This Is Your Brain On Drugs Psychiatry Podcast
von Cody Armstrong, MD
- wöchentlichErscheinungsrhythmus
- 54 mintypische Länge
- vor 6 Tagenletzte Folge
Join Cody Armstrong as he takes you on an adventure through psychiatric medications and beyond, breaking down these oft misunderstood drugs into easy, concise, and digestible pearls with his patented punk rock flare and a healthy dose of real science. Come explore these drugs like never before in fascinating detail whether you are a student, nurse, doc, patient, or just want to learn more. Listen to episodes on the podcast platform of your choice, follow along on YouTube with ease with slides and audio, or download slides at no cost at www.punkrockpsychiatrist.com. This Is Your Brain on Drugs Psychiatry Podcast will never charge you, show you an ad, or take sponsorship dollars from anyone because that just wouldn't be punk rock!
Folgen
E101: Antipsychotics: D2 and 5HT2A Receptor Activity
Today I will discuss how antipsychotics exert their positive effects on D2 and 5HT2A receptors. I will talk about intrinsic activity, partial agonism, pre-synaptic activity, antagonism, and the variety of effects the different antipsychotic
E100: Antipsychotics: Dosing
In today's episode I will go over how to dose antipsychotics. I will discuss the difference between the max dose on the package, the max clinical dose, and the dose at which you will get 95% effectiveness, and these are not always the same.
E99: Antipsychotics: Introduction
Today I will introduce you to the antipsychotics. I will go over the first and second generation antipsychotics. I will discuss their differences. I will go through each one and give details about when it came out and what it is approved fo
E98: Antipsychotics: Medical Work-up for Psychosis
Today I will continue with some more medical topics. I will discuss the medical causes of psychosis that need to be ruled out, and I will discuss how to do a proper medical work-up both in the emergency room and inpatient psychiatric unit f
E97: Antipsychotics: Schizophrenia: Psychogenic Polydipsia and Catatonia
In today's episode I will discuss two common disorders associated with schizophrenia and antipsychotic use: psychogenic polydipsia, a condition where patients feel a compulsion to drink water to the point of medical emergency, and catatonia
E96: Antipsychotics: Schizophrenia Diagnosis and Pathophysiology
On today's episode I will discuss the diagnostic symptoms and process for schizophrenia and related disorders. I will go over the symptoms in detail as well as the DSM criteria. I will then explain the hypothesis behind how we think this di
E95: Antipsychotics: Schizophrenia Background Information
I am starting a new season today, and I will be talking about antipsychotics. On today's episode I will be going over background information of schizophrenia: epidemiology, etiology, disease course, prognosis, and economic burden.
E94: Obesity Medicine: Weight Loss Procedures, Lipedema, and MASLD
This is the final episode in the obesity series. I will discuss weight loss procedures such as bariatric surgery and endoscopic procedures. I will then talk about lipedema and how it can cause obesity but should be treated differently. Last
E93: Obesity Medicine: GLP1s of the Future, Weight Loss Meds for Kids, and the Insurance Gauntlet
In today's episode I'm going to cover the GLP1 medications on the horizon. These include CagriSema, retatrutide, survodutide, and amycretin. Then I'll compare and contrast the currently approved GLP1s. I'll go over which weight loss medicat
E92: Obesity Medicine: GLP-1s: Saxenda, Wegovy, Zepbound, and Foundayo
Today I will be covering the GLP1 medications. Starting with exenatide and dulaglutide and then covering liraglutide (Saxenda), semaglutide (Wegovy), tirzepatide (Zepbound), and orforglipron (Foundayo). I'll go over how they are different,
E91: Obesity Medicine: GLP-1s: Eating Disorders, Drug Interactions, Shortages, Cost, and Compounding
Ok, so last time I discussed some of the downsides of GLP1 medications, and this will be part 2 of those downsides. First, I'll discuss eating disorders. How prescribing GLP1 medications in a world with eating disorders is complicated, and
E90: Obesity Medicine: GLP-1 Contraindications, Adverse Effects, and What To Do About It
Ok, so I've exalted the benefits of GLP1s and last time I went over how to customize to your patient. Today I will be going over some of the downsides. I'll cover the really serious stuff first that actually never happens in some cases or r
E89: Obesity Medicine: GLP-1 Dosing and Duration of Use
Today continuing with GLP-1 agonists, I will talk about the subtleties of dosing. It's a lot more than what the drug manufacturers publish. Simply following their simple instructions will not work for most patients, so I will discuss how to
E88 Obesity Medicine: GLP-1 Introduction, Mechanism, and Benefits
Today we finally reach the GLP-1 medications! It's been a long slog through obesity medication, but I feel like this is what everyone has been waiting for. I will start off today by telling you how these medications work on the many parts o
E87 Obesity Medicine: Medication: Other Medications
Today we will finish up on medications used for weight loss prior to going in to the GLP-1 medications. I will be discussing several medications today. These are medications that you will use less often, but most of them have important role
E86 ADHD: Effects of Menstrual Cycle and Perimenopause and Harder to Treat ADHD
Today is the last episode on ADHD, and I will finish off by talking about the effects of estrogen on ADHD symptoms both during the menstrual cycle and perimenopause. I will discuss using hormone replacement therapy as well as changes to ADH
E85: Obesity Medicine: Medication: Phentermine/Topiramate ER (Qsymia) and Naltrexone/Bupropion (Contrave)
Today I will continue with weight loss medications, and we will focus on two of the newer options. First the phentermine/topiramate ER combination pill known as Qsymia. Then I will talk about the naltrexone/bupropion combination pill known
E84: ADHD: Non-Stimulants Part 2: Guanfacine (Intuniv), Clonidine (Kapvay, Onyda XR), TCAs, Bupropion, Solriamfetol, Centanafadine, and Saffron
Today we will finish up the medications for ADHD with the remaining non-stimulant medications. There are actually quite a few non-stimulants with more than half being used off label. I will talk about the alpha 2 agonist medications guanfac
E83: Obesity Medicine: Medication: Phentermine, Vyvanse, and More Stimulants
We have finally finished going over lifestyle factors for obesity and mental health and will start talking about medications. Today I start with medications that you should be considering first line, including phentermine and several others
E82: ADHD: Non-Stimulants Part 1: Atomoxetine (Strattera) and Viloxazine (Qelbree)
Today we will be moving from the stimulant medications to the so called non-stimulants. Stimulants include methylphenidate and amphetamine as well as modafinil. There are actually quite a few non-stimulants with more than half being used of
E81: Obesity Medicine: Medical Assessment Before Starting Obesity Medications
We have finally finished going over lifestyle factors for obesity and mental health, and now if that was not enough to help the patient for weight loss and metabolic factors, we will need to consider using medications, but before we start m
E80: Obesity Medicine: Lifestyle Medicine: Sleep, Toxins, Social, Learning, and the Outdoors
Today I will be wrapping up the lifestyle factors that contribute to health problems like mental health and obesity. I will briefly discuss getting adequate sleep, avoiding toxins like alcohol, tobacco, and drugs, healthy relationships, lif
E79: ADHD: Stimulants: Adverse (Side) Effects Part 3: Substance Abuse Risk
Today I will wrap up the last episode on adverse effects of stimulant medications used to treat ADHD. I will be discussing the black box warning regarding abuse, misuse, and addiction. This risk is very much overstated, and it leads to prov
E33: Antidepressant Efficacy Part 3: The Case for Antidepressants
So we had two episodes on the efficacy of antidepressants and I think I may have been a little hard on them, so I decided to make a part 3 where I instill some hope in these medications. They work great for so many people, yet so many peopl
E31: Psychogenomic Testing (RePublish for Spotify)
I bet a lot of you have heard of psychogenomic testing or at least seen one. Maybe you are a patient and you got one or are thinking about getting one. Are these things worse the time and money? Listen to this episode to learn about them an
E30: Improving Efficacy of Medications (RePublish for Spotify)
On the last episode on antidepressant efficacy we discussed effect size and placebo. On today's episode I will cover a topic called psychodynamic prescribing. I'll be giving you tips on how to become a prescriber that gets max effect from m
E29: Efficacy of Antidepressants (RePublish for Spotify)
OK, so we've learned about the antidepressants, how to pick one, and how to dose. Well, how well do they work? I'll be discussing the efficacy of antidepressants on this episode, and I will be exploring the idea of placebo as it relates to
E78: Obesity Medicine: Lifestyle Medicine: Physical Fitness
So we've finally gone through the massive topic of nutrition, and today I'll just have this one episode on physical fitness. That's not because it isn't as important, but I think it's just a lot easier. With nutrition there's so much false
Quick Take #8: February Updates!: New Ketogenic Diet Studies for Mental Health Disorders, ProlivRX for Depression, New Blood Test for Alzheimers, and MORE!!!
It's been a few months since my last update episode, and I have several updates in the world of psychiatry. A couple studies of the ketogenic diet for depression and anxiety, a newly approved device for depression, a blood test for Alzheime
E77: ADHD: Stimulants: Adverse (Side) Effects Part 2: Cardiac and Pregnancy
Today I will continue talking about potential adverse effects of stimulant medications. Last time I discussed several adverse effects, but today I will mostly be focusing on cardiac (heart) effects because those have gotten a lot of press,
